SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
NORCROSS, Ga., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today Peter Traber, M.D., the Company’s president, chief executive officer and chief medical officer will present at the NobleCon12 - Noble Financial Capital Markets’ 12th Annual Investor Conference on January 20, 2016, at 9:30 a.m. Eastern Standard Time. The conference is being held at Club Med in Sandpiper Bay, Florida from January 17-20, 2016.
Following the conference on January 22, 2016, a high-definition video webcast of Galectin Therapeutics’ presentation and a copy of the presentation materials will be available on the Company's web site and a complete catalog of presentations will be available at Noble Financial websites: www.noblefcm.com, or www.nobleconference.com. You will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate. The webcast and presentation will be archived on the company's website and on the Noble websites for 90 days following the event.
About Galectin Therapeutics
Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.
About Noble Financial Capital Markets
Noble Financial Capital Markets established in 1984, is an equity-research driven, full-service, investment & merchant banking boutique focused on the healthcare, media & entertainment, technology and natural resources sectors. The company has offices in Boca Raton, New York, Boston and Los Angeles. In addition to the annual multi-sector NobleCon, each year Noble hosts numerous “non-deal” corporate road shows and sector-specific conferences. Members: FINRA, SIPC, MSRB. www.noblefcm.com
Contacts
Jack Callicutt, Chief Financial Officer
(678) 620-3186
[email protected]
LHA
Kim Golodetz
(212) 838-3777
[email protected]
Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc.
